Molecular Subtype Distribution and Cyclooxygenase-2 Expression Situation in Inflammatory Breast Cancer
Makaleler > Tam Makale · 2016
Yazarlar: Pusem PATIR, Burcak KARACA, Alper SENER, Osman ZEKİOĞLU, Güray SAYDAM, Canfeza SEZGİN
Meandros Medical and Dental Journal, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2016, cilt 17, ss 54-58
Özet
Objective: Inflammatory breast cancer (IBC) is a rare and aggressive form of locally advanced breast cancer.Currently, almost all women with IBC have lymph node involvement and approximately one-third have distant metastases.Therefore, there is still need for understanding of the molecular biology and new therapy alternatives in IBC.The purpose of this study was to determine the potential role of the cyclooxygenase-2 (COX-2) expression pattern in the aggressive and fatal course of IBC and to investigate the possibility of using COX-2 inhibitors as therapy options in the treatment of IBC. Materials and Methods: IBC samples obtained from breast cancer patients treated Between 2000-2009 in Ege University Faculty of Medicine Department of Medical Oncology were retrospectively evaluated.Immunohistochemical analysis was performed by a special breast cancer pathologist and manually assessed using an immunohistochemical scoring for both staining intensity and percentage.Results: In this study, the molecular subtypes identified in IBC patients were: basal (31%), luminal B/human epidermal growth factor receptor 2 (HER2)-(22%), luminal B/HER2+ (22%), HER2 (17%) and luminal A (8%).COX-2 expression was found to be positive in 92.6% of patients.Conclusion: In this context, it was concluded that the relatively high expression rate of COX-2 could be a reason for poor prognosis and also might lead to the use of COX-2 inhibitors not only as a single agent but also in combination with current chemotherapeutic agents in patients with IBC.Öz Amaç: Enflamatuvar meme kanseri (EMK), lokal ilerlemiş meme kanserinin agresif bir alt tipidir.Günümüzde EMK'lı kadınların hemen hepsi lenf nodu tutulumuna ve yaklaşık üçte biri de uzak metastaza sahiptir.Bu yüzden EMK'nın moleküler biyolojisinin anlaşılmasına ve yeni tedavi seçeneklerine ihtiyaç vardır.Bu çalışmanın amacı EMK'nın agresif ve fatal seyrinde moleküler doğasının rol oynayabileceğini ve siklooksijenaz-2 inhibitörlerinin EMK tedavisinde hedefe yönelik tedavi seçeneği olabileceğini göstermektir.Gereç ve Yöntemler: Ege Üniversitesi Tıp Fakültesi Medikal Onkoloji Anabilim Dalı'nda 2000-2009 yıllarında meme kanseri tedavisi gören hastalardan sağlanan EMK örnekleri retrospektif olarak değerlendirildi.İmmünohistokimyasal analiz özel Enflamatuvar Meme Kanserinde Moleküler Alt Tip Dağılımı ve Siklooksijenaz-2 Ekspresyon Durumu Molecular Subtype Distribution and Cyclooxygenase-2 Expression Situation in Inflammatory Breast Cancer